The promise of retinoids to fight against cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Retinoids have a reputation for being both detrimental and beneficial: they are teratogens, but they also have tumour-suppressive capacity. Cell biology and genetics have significantly improved our understanding of the mechanisms that underlie the anti-proliferative action of retinoids. Recent elucidation of the pathways that are activated by retinoids will help us to exploit the beneficial aspects of this powerful class of compounds for cancer therapy and prevention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apart from the well-known indications in hypovitaminosis and skin diseases, retinoids have been successfully used in treating cancer”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [187]
In the citing paper
“The FDA has approved ATRA to treat cystic acne and several cancers, such as some lymphoma and leukemia”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [187]
Citations
Cites
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233 · cited 8×
“a | The t(15;17) chromosomal translocation generates the PML–RARα fusion protein that, in contrast to RARα, can efficiently dimerize or oligomerize, thereby recruiting multiple HDAC complexes and leading to ‘super-repression’ of target genes.”
BackgroundInfluentialKamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81118-6 · Cited by 2,150
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics
McPherson, K. (2000) · BMJ · doi:10.1136/bmj.321.7261.624 · Cited by 1,570
Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., Peters, L. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199009203231205 · Cited by 1,365
The retinoids—Biology, chemistry and medicine
(1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)80793-5 · Cited by 1,178
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Embryonic retinoic acid synthesis is essential for early mouse post-implantation development
Niederreither, K., Subbarayan, V., Dollé, P., & Chambon, P. (1999) · Nature Genetics · doi:10.1038/7788 · Cited by 1,077
Role of the histone deacetylase complex in acute promyelocytic leukaemia
Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., & Evans, R. M. (1998) · Nature · doi:10.1038/35895 · Cited by 1,062 · cited 1×
“However, high concentrations of HDAC inhibitors (HDACi) can convert even PLZF–RARα into an activator of the RA signalling pathwa”
BackgroundGrignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) · Nature · doi:10.1038/35901 · Cited by 1,004 · cited 1×
“However, high concentrations of HDAC inhibitors (HDACi) can convert even PLZF–RARα into an activator of the RA signalling pathwa”
Background
Research works printed but not linked: 1
- Moon, R. C., Mehta, R. G. & Rao, K. J. V. N. in The Retinoids (eds Sporn, M. B., Roberts, A. B. & Goodman, D. S.) 573–595 (Raven, New York, 1994).
Cited by
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
“The JNK/JUN pathway regulates a plethora of target genes that contain AP1-binding sites, including genes that control the cell cycle, as well as survival and apoptosis, metalloproteinases and nuclear hormone receptors, such as retinoid receptor”
BackgroundAP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1209 · Cited by 2,242
“In at least some of these cases, the tumour-suppressive activity of retinoic acids is mediated by transrepression of AP-1 (Ref”
BackgroundPrinciples for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
“Whether and how this distinct characteristic of RARβ is linked to its presumptive role as a tumour supressor remains to be established (see Ref”
BackgroundSelf-citationNuclear retinoid receptors and the transcription of retinoid-target genes
Bastien, J., & Rochette-Egly, C. (2004) · Gene · doi:10.1016/j.gene.2003.12.005 · Cited by 773
“The repressive effect of retinoids on AP-1 activity has been correlated with their antitumor activity and the importance of this cross-talk for growth control is increasingly recognized (Altucci and Gronemeyer, 2001b).”
BackgroundInfluentialThe Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610
“Together with our previous studies showing that the cancer therapeutic action of retinoid”
MethodSelf-citationCancer Chemoprevention by Carotenoids
Tanaka, T., Shnimizu, M., & Moriwaki, H. (2012) · Molecules · doi:10.3390/molecules17033202 · Cited by 589
“Recent elucidation of the pathways that are activated by retinoids will help to exploit the beneficial aspects of this class of compounds for cancer therapy and prevention [219,220].”
BackgroundAndresen, T. L., Jensen, S. S., & Jørgensen, K. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.12.001 · Cited by 580
A Microenvironment-Induced Myeloproliferative Syndrome Caused by Retinoic Acid Receptor γ Deficiency
Walkley, C. R., Olsen, G. H., Dworkin, S., Fabb, S. A., Swann, J., McArthur, G. A., Westmoreland, S. V., Chambon, P., Scadden, D. T., & Purton, L. E. (2007) · Cell · doi:10.1016/j.cell.2007.05.014 · Cited by 536
“Retinoic acid receptors (RARs) have been associated with many different diseases, including cancer, and retinoid-based therapies are increasingly being utilized to treat such disorders (Altucci and Gronemeyer, 2001).”
RAR and RXR modulation in cancer and metabolic disease
Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2397 · Cited by 517
“As numerous preclinical and clinical data have already been reviewe”
BackgroundSelf-citationInternational Union of Pharmacology. LXIII. Retinoid X receptors
Germain, P., Chambon, P., Eichele, G., Evans, R. M., Lazar, M. A., Leid, M., De Lera, A. R., Lotan, R., Mangelsdorf, D. J., & Gronemeyer, H. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.7 · Cited by 496
“Ligand activation of RXRs has potentially pleiotropic effects on numerous biological pathways and hence therapeutic opportunities, as demonstrated by the clinical use of RXR-selective ligands, referred to as rexinoids, for the treatment of cancer and metabolic diseases (Thacher et al., 2000; Altucci and Gronemeyer, 20…”
BackgroundSelf-citationDNA methylation and breast carcinogenesis
Widschwendter, M., & Jones, P. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205606 · Cited by 457
“This complex attracts histone deacetylases to an area surrounding RAREs to remove acetyl groups from nucleosomal histones, resulting in chromatin condensation and gene silencing (reviewed in Altucci and Gronemeyer, 2001).”
BackgroundBiomarkers of Nutrition for Development (BOND)-Vitamin A Review
Tanumihardjo, S. A., Russell, R. M., Stephensen, C. B., Gannon, B. M., Craft, N. E., Haskell, M. J., Lietz, G., Schulze, K., & Raiten, D. J. (2016) · The Journal of Nutrition · doi:10.3945/jn.115.229708 · Cited by 451
The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling
Epping, M. T., Wang, L., Edel, M. J., Carlée, L., Hernandez, M., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.07.003 · Cited by 432
“Loss of RARβ expression is involved in the progression of a diverse range of solid tumors, including breast and lung carcinomas (Altucci and Gronemeyer, 2001; Freemantle et al., 2003).”
Mechanism of All- Trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells
Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A. A., & Gabrilovich, D. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2593 · Cited by 423
“RAREs have been identified in the promoters of a large number of retinoid target genes implicated in a wide variety of functions (14).”
BackgroundCarazo, A., Macáková, K., Matoušová, K., Krčmová, L. K., Protti, M., & Mladěnka, P. (2021) · Nutrients · doi:10.3390/nu13051703 · Cited by 461
Vitamin A and retinoid signaling: genomic and nongenomic effects
Al Tanoury, Z., Piskunov, A., & Rochette-Egly, C. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r030833 · Cited by 408
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
International Union of Pharmacology. LX. Retinoic Acid Receptors
Germain, P., Chambon, P., Eichele, G., Evans, R. M., Lazar, M. A., Leid, M., De Lera, A. R., Lotan, R., Mangelsdorf, D. J., & Gronemeyer, H. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.4 · Cited by 397
“Clarke N, Nebbioso A, Altucci L, and Gronemeyer H (2005) TRAIL: at the center of drugable anti-tumor pathways.”
BackgroundMethodInfluentialSelf-citationThe experimental power of FR900359 to study Gq-regulated biological processes
Schrage, R., Schmitz, A.-L., Gaffal, E., Annala, S., Kehraus, S., Wenzel, D., Büllesbach, K. M., Bald, T., Inoue, A., Shinjo, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms10156 · Cited by 368
Nevoid basal cell carcinoma (Gorlin) syndrome
Gorlin, R. J. (2004) · Genetics in Medicine · doi:10.1097/01.gim.0000144188.15902.c4 · Cited by 366
Retinoic Acid Enhances Foxp3 Induction Indirectly by Relieving Inhibition from CD4+CD44hi Cells
Hill, J. A., Hall, J. A., Sun, C.-M., Cai, Q., Ghyselinck, N., Chambon, P., Belkaid, Y., Mathis, D., & Benoist, C. (2008) · Immunity · doi:10.1016/j.immuni.2008.09.018 · Cited by 357
“Beyond their direct effects as transactivators, RARs also influence transcription by transrepression of AP-1 activity (Nicholson et al., 1990; Salbert et al., 1993; Chen et al., 1995; Altucci and Gronemeyer, 2001).”
BackgroundThe many faces of the adamantyl group in drug design
Liu, J., Obando, D., Liao, V., Lifa, T., & Codd, R. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.047 · Cited by 309
Galasso, C., Gentile, A., Orefice, I., Ianora, A., Bruno, A., Noonan, D. M., Sansone, C., Albini, A., & Brunet, C. (2019) · Nutrients · doi:10.3390/nu11061226 · Cited by 295
Retinoic acid signaling and neuronal differentiation
Janesick, A., Wu, S. C., & Blumberg, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1815-9 · Cited by 295
“HDAC inhibitors increase RA sensitivity by promoting dissociation of repressive complexes from RAR, thus, accelerating the differentiation process [230, 231].”
BackgroundNuclear receptors: integration of multiple signalling pathways through phosphorylation
Rochette-Egly, C. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00115-8 · Cited by 291
Retinoic acid signaling pathways in development and diseases
Das, B. C., Thapa, P., Karki, R., Das, S., Mahapatra, S., Liu, T.-C., Torregroza, I., Wallace, D. P., Kambhampati, S., Van Veldhuizen, P., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.11.025 · Cited by 276
Reactivating the expression of methylation silenced genes in human cancer
Karpf, A. R., & Jones, D. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205602 · Cited by 264
“An intriguing link between 5-aza-CdR and retinoic acid is that they each are potent inducers of cellular differentiation (Altucci and Gronemeyer, 2001; Jones and Taylor, 1980).”
BackgroundFunctions, Therapeutic Applications, and Synthesis of Retinoids and Carotenoids
Álvarez, R., Vaz, B., Gronemeyer, H., & de Lera, Á. R. (2014) · Chemical Reviews · doi:10.1021/cr400126u · Cited by 260
Self-citationTargeting cytochrome P450 enzymes: A new approach in anti-cancer drug development
Bruno, R. D., & Njar, V. C. O. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.05.046 · Cited by 249
Notch tumor suppressor function
Dotto, G. P. (2008) · Oncogene · doi:10.1038/onc.2008.225 · Cited by 244
Promise and challenges in drug discovery and development of hybrid anticancer drugs
Gediya, L. K., & Njar, V. C. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903341705 · Cited by 222
“4 All-trans retinoic acid–butyric acid (5) All-trans retinoic acid (ATRA) is reported to induce differentiation and arrest proliferation in a wide spectrum of cancer cells [31].”
BackgroundGenomic landscapes of breast fibroepithelial tumors
Tan, J., Ong, C. K., Lim, W. K., Ng, C. C. Y., Thike, A. A., Ng, L. M., Rajasegaran, V., Myint, S. S., Nagarajan, S., Thangaraju, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3409 · Cited by 218
LSD1: more than demethylation of histone lysine residues
Perillo, B., Tramontano, A., Pezone, A., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00542-2 · Cited by 214
Tewari, D., Nabavi, S. F., Nabavi, S. M., Sureda, A., Farooqi, A. A., Atanasov, A. G., Vacca, R. A., Sethi, G., & Bishayee, A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.014 · Cited by 205
“These comounds are considered capable of mitigation and prevention of arious cancers via their ability to stimulate tumor cell apoptois and cell growth suppression [71,72].”
BackgroundHepatic metabolism of retinoids and disease associations
Shirakami, Y., Lee, S.-A., Clugston, R. D., & Blaner, W. S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.06.023 · Cited by 203
Enzyme-triggered nanomedicine: Drug release strategies in cancer therapy (Invited Review)
Andresen, T. L., Thompson, D. H., & Kaasgaard, T. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.515950 · Cited by 200
“Polyunsaturated fatty acids (Siddiqui et al. 2001), retinoids (Altucci & Gronemeyer 2001) or prostaglandins (Straus & Glass 2001) are some of the more attractive candidates for this strategy.”
BackgroundBetween Death and Survival: Retinoic Acid in Regulation of Apoptosis
Noy, N. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155509 · Cited by 193
BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect
Hallahan, A. R., Pritchard, J. I., Chandraratna, R. A. S., Ellenbogen, R. G., Geyer, J. R., Overland, R. P., Strand, A. D., Tapscott, S. J., & Olson, J. M. (2003) · Nature Medicine · doi:10.1038/nm904 · Cited by 192
“jpg" NDATA ITEM> ]> Although retinoids induce differentiation and apoptosis in numerous cancers, their pleiotropic effects have largely confounded previous attempts to characterize specific proteins that mediate retinoid-induced cell deat”
BackgroundMein, J. R., Lian, F., & Wang, X.-D. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2008.00120.x · Cited by 191
“81 The mechanism by which retinoids elicit these responses is through their ability to regulate gene expression at specific target sites within the body.”
Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein
Yang, Q., Deng, X., Lu, B., Cameron, M., Fearns, C., Patricelli, M. P., Yates, J. R., Gray, N. S., & Lee, J.-D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.008 · Cited by 187
Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?
Dashwood, R. H., Myzak, M. C., & Ho, E. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi253 · Cited by 186
Liu, L., & Gudas, L. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509643200 · Cited by 181
Vitamin A and the regulation of fat reserves
Bonet, M. L., Ribot, J., Felipe, F., & Palou, A. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-2290-x · Cited by 174
Cancer Chemoprevention by Targeting the Epigenome
Huang, J., Plass, C., & Gerhauser, C. (2011) · Current Drug Targets · doi:10.2174/138945011798184155 · Cited by 169
“In several clinical studies, retinoids were applied to individuals at increased risk of developing cancer, for example those with premalignant lesions or at risk to develop a second primary tumor (summarized in [102, 103]).”
Backgroundvan der Ven, A. T., Vivante, A., & Hildebrandt, F. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017050561 · Cited by 162
Differentiation therapy of acute myeloid leukemia: past, present and future
Petrie, K., Zelent, A., & Waxman, S. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257aee · Cited by 161
Unlocking the potential of retinoic acid in anticancer therapy
Schenk, T., Stengel, S., & Zelent, A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.412 · Cited by 160
“Effects of ATRA on tumour development are extensive and include differentiation and apoptosis induction, as well as tumour prevention (Altucci and Gronemeyer, 2001).”
BackgroundPili, R., Salumbides, B., Zhao, M., Altiok, S., Qian, D., Zwiebel, J., Carducci, M. A., & Rudek, M. A. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.527 · Cited by 157
“Previous clinical trials involving retinoids as single agents have shown no significant clinical activity in patients with epithelial cancer (Altucci and Gronemeyer, 2001).”
BackgroundInfluentialRole of mitogen-activated protein kinase kinase 4 in cancer
Whitmarsh, A. J., & Davis, R. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210410 · Cited by 175
“There is evidence that retinoid receptors can suppress tumorigenesis and that the loss of specific receptors promotes carcinogenesis in many tissues (Altucci and Gronemeyer, 2001).”
BackgroundLorenzo, Y., Azqueta, A., Luna, L., Bonilla, F., Dominguez, G., & Collins, A. R. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn270 · Cited by 155
Hess‐Stumpp, H., Bracker, T. U., Henderson, D. A., & Politz, O. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.009 · Cited by 165
Quintás‐Cardama, A., Santos, F. P. D. S., & Garcia‐Manero, G. (2010) · Leukemia · doi:10.1038/leu.2010.276 · Cited by 166
Mechanistic aspects of carotenoid health benefits – where are we now?
Bohn, T., Bonet, M. L., Borel, P., Keijer, J., Landrier, J., Milisav, I., Ribot, J., Riso, P., Winklhofer‐Roob, B. M., Sharoni, Y., et al. (2021) · Nutrition Research Reviews · doi:10.1017/s0954422421000147 · Cited by 172
“Further inspection of the FZD6 and β-carotene controlled genes revealed a strong enrichment of genes controlled by the transcription factors JUN (the target of JNK) and activating transcription factor 2 (ATF2, a major target of MAPK14)(326).”
InfluentialKamashev, D., Vitoux, D., & de Thé, H. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032226 · Cited by 153
“This pathway could be active in non-APL leukemias and extend the concept of differentiation therapy to other hematological malignancies (21).”
BackgroundXiao, J.-H., Ghosn, C., Hinchman, C., Forbes, C., Wang, J., Snider, N., Cordrey, A., Zhao, Y., & Chandraratna, R. A. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304761200 · Cited by 148
Vitamin A, Cancer Treatment and Prevention: The New Role of Cellular Retinol Binding Proteins
Doldo, E., Costanza, G., Agostinelli, S., Tarquini, C., Ferlosio, A., Arcuri, G., Passeri, D., Scioli, M. G., & Orlandi, A. (2015) · BioMed Research International · doi:10.1155/2015/624627 · Cited by 147
“Natural and synthetic retinoids have been demonstrated to inhibit the growth and the development of different types of tumours, including skin, breast, oral cavity, lung, hepatic, gastrointestinal, prostatic, and bladder cancers [33–37].”
BackgroundNjar, V. C. O., Gediya, L. K., Purushottamachar, P., Chopra, P., Vasaitis, T. S., Khandelwal, A., Mehta, J., Huynh, C., Belosay, A., & Patel, J. B. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.02.041 · Cited by 169
Huang, S., Laoukili, J., Epping, M. T., Koster, J., Hölzel, M., Westerman, B. A., Nijkamp, W., Hata, A., Asgharzadeh, S., Seeger, R. C., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.023 · Cited by 145
“Consequently, RA displays distinct anticarcinogenic activities, and it is currently in use or being tested as a therapeutic agent for several human cancers (Altucci and Gronemeyer, 2001; Freemantle et al., 2003).”
Tumor suppressor IRF‐1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL
Clarke, N., Jimenez-Lara, A. M., Voltz, E., & Gronemeyer, H. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600302 · Cited by 163
“The second unresolved question concerns the tumor suppressive function of RARb2, which is frequently deleted or epigenetically silenced during cancer progression (re- viewed by Altucci and Gronemeyer, 2001) and may be related to particularities of RARb (Germain et al, 2002).”
InfluentialSelf-citationFarol, L. T., & Hymes, K. B. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.2.180 · Cited by 136
Zhao, X., Patton, J. R., Davis, S. L., Florence, B., Ames, S. J., & Spanjaard, R. A. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.06.044 · Cited by 152
Harwood, C. A., Leedham-Green, M., Leigh, I. M., & Proby, C. M. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.4.456 · Cited by 138
“ence transcription of specific genes, with a consequent wide range of biological activities.(7) Possible mechanisms by which they prevent or reduce development of skin cancer include induction of growth arrest or apoptosis of tumor cells with resultant inhibition of tumor differentiation and promotion, induction of no…”
BackgroundThe molecular physiology of nuclear retinoic acid receptors. From health to disease
Duong, V., & Rochette‐Egly, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.10.007 · Cited by 157
Ma, G., Zhang, L., Kato, M., Yamawaki, K., Kiriiwa, Y., Yahata, M., Ikoma, Y., & Matsumoto, H. (2011) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf203364m · Cited by 137
Immediate early response genes and cell transformation
Healy, S., Khan, P., & Davie, J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.001 · Cited by 162
Pharmacological Inhibition of LSD1 for Cancer Treatment
Yang, G., Lei, P.-M., Wong, S.-Y., Ma, D., & Leung, C. (2018) · Molecules · doi:10.3390/molecules23123194 · Cited by 138
“This compound exhibited good in vitro and in vivo anti-cancer activity in mouse models of AML and Ewing sarcoma [97,98].”
BackgroundInfluentialPogenberg, V., Guichou, J.-F., Vivat-Hannah, V., Kammerer, S., Pérez, E., Germain, P., de Lera, A. R., Gronemeyer, H., Royer, C. A., & Bourguet, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409302200 · Cited by 128
Self-citationTransport proteins of the ABC family and multidrug resistance of tumor cells
Stavrovskaya, A. A., & Stromskaya, T. P. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908050118 · Cited by 146
Ondrey, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0326 · Cited by 126
Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?
Gruning, T., Tiepolt, C., Zophel, K., Bredow, J., Kropp, J., & Franke, W. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480395 · Cited by 126
“modulate the transcription of target genes by binding to retinoic acid response elements (RARE) in their promoter [9].”
BackgroundNSAID Sulindac and Its Analog Bind RXRα and Inhibit RXRα-Dependent AKT Signaling
Zhou, H., Liu, W., Su, Y., Wei, Z., Liu, J., Kolluri, S. K., Wu, H., Cao, Y. J., Chen, J., Wu, Y., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.023 · Cited by 134
Chung, S. S. W., Wang, X., Roberts, S. S., Griffey, S. M., Reczek, P. R., & Wolgemuth, D. J. (2011) · Endocrinology · doi:10.1210/en.2010-0941 · Cited by 122
Germain, P., Gaudon, C., Pogenberg, V., Cianférani, S., DORSSELAER, A. V., Royer, C. A., Lazar, M. A., Bourguet, W., & Gronemeyer, H. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.03.008 · Cited by 121
“…constitute the molecular basis of ligand-mediated coregulator exchange on NRs. Retinoids and rexinoids (RXR-selective ligands) have significant promise for the treatment and prevention of cancer and other diseases (Altucci and Gronemeyer,2001; Altucci et al., 2007; Shulman and Mangelsdorf, 2005).”
Self-citationDonato, L. J., Suh, J. H., & Noy, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-0989 · Cited by 118
“www.aacrjournals.org 609 Cancer Res 2007; 67: ( 2 ).”
InfluentialImpairment of p53 acetylation, stability and function by an oncogenic transcription factor
Insinga, A., Monestiroli, S., Ronzoni, S., Carbone, R., Pearson, M. A., Pruneri, G., Viale, G., Appella, E., Pelicci, P. G., & Minucci, S. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600109 · Cited by 130
“direct effects of HDACi on an oncogenic transcription factor (PML–RAR) add to the more general, previously described effects of HDACi on cancer cells, and lend further support to their use in cancer therapy (Altucci and Gronemeyer, 2001; Marks et al, 2001; Minucci et al, 2001).”
BackgroundInfluentialHistone deacetylase inhibitors and cancer: from cell biology to the clinic
Hess‐Stumpp, H. (2005) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2004.12.010 · Cited by 128
Retinoids: potential in cancer prevention and therapy
Clarke, N., Germain, P., Altucci, L., & Gronemeyer, H. (2004) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399404008488 · Cited by 115
Self-citationHarris, M. N., Özpolat, B., Abdi, F. A., Gu, S., Legler, A., Mawuenyega, K. G., Tírado-Gómez, M., Lopez‐Berestein, G., & Chen, X. (2004) · Blood · doi:10.1182/blood-2004-01-0046 · Cited by 123
Saavalainen, K., Pasonen‐Seppänen, S., Dunlop, T. W., Tammi, R., Tammi, M., & Carlberg, C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500206200 · Cited by 130
Bontempo, P., Mita, L., Miceli, M., Doto, A., Nebbioso, A., Bellis, F. D., Conte, M., Minichiello, A., Manzo, F., Carafa, V., et al. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.05.010 · Cited by 141
Self-citationAltucci, L., Rossin, A., Hirsch, O., Nebbioso, A., Vitoux, D., Wilhelm, E., Guidez, F., De Simone, M., Schiavone, E. M., Grimwade, D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3569 · Cited by 114
“As differentiation generally limits the proliferative capacity and life span of a cell, agents able to restore normal differentiation pathways in cancer cells and/or induce postmaturation apoptosis are promising tools for cancer therapy (6, 8, 19, 44).”
Self-citationMrass, P., Rendl, M., Mildner, M., Gruber, F., Lengauer, B., Ballaun, C., Eckhart, L., & Tschachler, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1129 · Cited by 112
“Apoptosis in this setting has been attributed to the induction of tumor necrosis factorrelated apoptosis-inducing ligand expression by retinoids and its paracrine effect on tumor cells (1).”
BackgroundResultInfluentialCho, E., Hunter, D. J., Spiegelman, D. L., Albanes, D., Beeson, W. L., van den Brandt, P. A., Colditz, G. A., Feskanich, D., Folsom, A. R., Fraser, G. E., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21441 · Cited by 113
Matt, N., Ghyselinck, N. B., Wendling, O., Chambon, P., & Mark, M. (2003) · Development · doi:10.1242/dev.00428 · Cited by 109
Mechanisms of Resistance to Histone Deacetylase Inhibitors
Lee, J., Choy, M. L., & Marks, P. A. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00002-1 · Cited by 116
Maru, G. B., Hudlikar, R. R., Kumar, G., Gandhi, K., & Mahimkar, M. B. (2016) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v7.i1.88 · Cited by 111
Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators
le Maire, A., Alvarez, S., Shankaranarayanan, P., R de Lera, A., Bourguet, W., & Gronemeyer, H. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436687 · Cited by 105
“The development and characterization of highly potent and selective retinoid receptor modulators have provided detailed understanding of their involvement in multiple physiological phenomena and their cancer-therapeutic potential is well documented [4, 5].”
BackgroundSelf-citationPremenopausal intakes of vitamins A, C, and E, folate, and carotenoids, and risk of breast cancer.
Cho, E., Spiegelman, D. L., Hunter, D. J., Chen, W. Y., Zhang, S. M., Colditz, G. A., & Willett, W. C. (2003) · PubMed · Cited by 105
Varley, C. L., Stahlschmidt, J., Smith, B. A., Stower, M. J., & Southgate, J. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63737-6 · Cited by 107
“RXR binds 9-cis-RA with high affinity, whereas RARs interact with 9-cis-, 13-cis-, and all-trans RA.(12) We have shown previously that normal human urothelial (NHU) cells grown in vitro in the absence of exogenous retinoids express a squamous-associated CK13 , CK14 phenotype, but revert to a transitional CK13 , CK14 p…”
BackgroundMethodInfluentialThe molecular mechanism of HDAC inhibitors in anticancer effects.
Bi, G., & Jiang, G. (2006) · PubMed · Cited by 100
Non-melanoma skin cancer: carcinogenesis and chemoprevention
Chen, A. C., Halliday, G. M., & Damian, D. L. (2013) · Pathology · doi:10.1097/pat.0b013e32835f515c · Cited by 116
“Retinoids work by regulating proliferation, differentiation and apoptosis.(143) Several clinical trials have demonstrated retinoids to be an effective chemopreventive agent for NMSCs.”
BackgroundVarshosaz, J., & Farzan, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i42.12022 · Cited by 105
Huang, G., Chen, Y., Lu, H. K., & Cao, X. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402004 · Cited by 104
A Causal Role for the Human Tumor Antigen Preferentially Expressed Antigen of Melanoma in Cancer
Epping, M. T., & Bernards, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2522 · Cited by 97
“The resulting fusion proteins encode functionally altered receptors, which are constitutive repressors of RA-induced differentiation of leukemic blasts (20).”
BackgroundFunctional Implication of the Vitamin A Signaling Pathway in the Brain
Tafti, M., & Ghyselinck, N. B. (2007) · Archives of Neurology · doi:10.1001/archneur.64.12.1706 · Cited by 99
“Since the original description of the congenital ocular malformation due to vitamin A deficiency,(1) many clinical and experimental findings have indicated that vitamin A and its active derivatives, retinoids, play a major role in embryogenesis, cell proliferation and differentiation, and apoptosis.(2,3) Aside from vi…”
BackgroundSystemic and Topical Retinoids in the Management of Skin Cancer in Organ Transplant Recipients
de Graaf, Y. G. L., Euvrard, S., & Bavinck, J. N. B. (2004) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2004.30152.x · Cited by 93
Epigenetics and the plasticity of differentiation in normal and cancer stem cells
Lotem, J., & Sachs, L. (2006) · Oncogene · doi:10.1038/sj.onc.1209816 · Cited by 104
“…differentiation can bypass the genetic abnormalities in cancer, and this epigenetic reprogramming is the basis for differentiation therapy of cancer (Sachs, 1978; Altucci and Gronemeyer, 2001; Degos and Wang, 2001; He et al., 2001; Marks et al., 2001; Zhang et al., 2001; Lotem and Sachs, 2002b).”
BackgroundOzpolat, B., Akar, U., Steiner, M., Zorrilla-Calancha, I., Tirado-Gomez, M., Colburn, N., Danilenko, M., Kornblau, S., & Lopez Berestein, G. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0125 · Cited by 93
“a complex process that requires transcriptional and translational regulation of many specific targets (6-9).”
Background
Metadata
- Authors
- Altucci, L., & Gronemeyer, H.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Venue
- Nature Reviews Cancer
- Published
- 2001-12
- Volume
- 1
- Issue
- 3
- Pages
- 181-193
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1964224609
- Cited by
- 773
- References
- 147
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 16 · 2023: 18 · 2022: 12 · 2021: 16 · 2020: 20 · 2019: 19 · 2018: 20 · 2017: 28 · 2016: 25 · 2015: 36 · 2014: 25 · 2013: 32 · 2012: 47
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- retinoids, cancer therapy, cancer prevention, tumor suppression, antiproliferative mechanism, teratogenicity, cell proliferation
- MeSH terms
- Antineoplastic Agents, Cell Differentiation, Forecasting, Humans, Models, Biological, Morphogenesis, Neoplasm Proteins, Neoplasms, Retinoids, Skin Neoplasms, Structure-Activity Relationship, Vitamin A, Leukemia, Promyelocytic, Acute, Oncogene Proteins, Fusion, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Anticarcinogenic Agents, Apoptosis, Receptors, Retinoic Acid, Transcription Factor AP-1, Dimerization, Receptor Cross-Talk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.